Leading Cogstate in our focus to optimize the measurement of cognition
Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. He has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.
Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods.
Ken Billard is the Chief Commercial Officer for Cogstate, where he develops and executes strategies focused on expanding the adoption of Cogstate solutions to optimize the measurement of cognition and other clinical outcome assessments in pharmaceutical clinical trials.
Dr. Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the development of new technologies.
Brendan Owen has been leading Software Development at Cogstate since joining the company in 2012. In January 2020 Brendan was appointed as Interim Chief Technology Officer. In the role of Interim CTO, Brendan manages Cogstate’s global software development and technology teams to deliver quality software and products.
Kate Jopling is Vice President of Operations for Clinical Trials at Cogstate. She has led the global Clinical Trials Operations division since 2014. In her role, Kate sets the strategic direction for delivery of products and services aimed at helping pharmaceutical clinical trials sponsors, CROs, and sites optimize the measurement of cognition with eClinical technologies and customized solutions.
Rachel brings more than 15 years of life science marketing strategy experience to her role at Cogstate, including marketing management roles at ICON plc (Nasdaq: ICLR), a global provider of outsourced development services to the biopharmaceutical industry.
Tanya brings over 15 years’ experience in product development and operational management of clinical research to her role at Cogstate, specifically focussed on the measurement of cognition. She is skilled in new product and service implementation, leading and managing dynamic teams and process improvement initiatives.
John joined Cogstate as General Counsel in February 2020. Previously, John was the Chief Compliance Officer, Assistant General Counsel and Assistant Secretary for Axogen Inc. John has over 20 years legal experience, including prior in-house positions with multi-national medical technology companies Medtronic and Covidien.
Keith has responsibility for the Financial functions at Cogstate. He is a senior finance professional CPA with experience in various industries including healthcare, engineering, aerospace, IT and humanitarian aid, offering exposure to acquisition and greenfield sites throughout the Asia Pacific region.
Mala has over 25 years of experience in the Quality field and has been managing the Quality Department at Cogstate since she joined in 2006. As the Head of the Quality Department at Cogstate, Mala leads the Quality team in the implementation and maintenance of a robust quality management system including system validations, managing sponsor audits and regulatory inspections.
Cogstate’s cognitive scientists and statisticians are experienced with all aspects of clinical conduct, from study design to cognitive data interpretation. Meet our team of accomplished neuropsychologists and clinicians.